What is HC Wainwright’s Forecast for OCUL Q1 Earnings?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for Ocular Therapeutix in a research note issued on Thursday, May 29th. HC Wainwright analyst Y. Chen anticipates that the biopharmaceutical company will earn ($0.37) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.37) EPS and Q4 2026 earnings at ($0.35) EPS.

Other equities analysts have also issued research reports about the stock. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. William Blair assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They set an “outperform” rating for the company. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They set an “outperform” rating and a $17.00 price target for the company. Finally, Needham & Company LLC reduced their price target on shares of Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $16.25.

Ocular Therapeutix Price Performance

OCUL opened at $8.01 on Monday. The firm has a market cap of $1.28 billion, a P/E ratio of -6.07 and a beta of 1.51. The firm has a 50-day moving average of $7.37 and a 200 day moving average of $7.90. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. Ocular Therapeutix has a fifty-two week low of $4.79 and a fifty-two week high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). The company had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%.

Insiders Place Their Bets

In other news, Director Richard L. Md Lindstrom acquired 10,000 shares of the business’s stock in a transaction dated Thursday, May 8th. The stock was bought at an average cost of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the transaction, the director now owns 172,704 shares of the company’s stock, valued at $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Pravin Dugel sold 21,219 shares of the firm’s stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the transaction, the insider now owns 3,499,099 shares of the company’s stock, valued at $25,123,530.82. This trade represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,079 shares of company stock worth $208,739 over the last quarter. 2.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ocular Therapeutix

Large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in shares of Ocular Therapeutix in the fourth quarter valued at approximately $28,000. Brooklyn Investment Group raised its stake in Ocular Therapeutix by 151.5% in the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 3,155 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new stake in Ocular Therapeutix in the fourth quarter valued at approximately $43,000. AlphaQuest LLC purchased a new stake in Ocular Therapeutix in the fourth quarter valued at approximately $53,000. Finally, GAMMA Investing LLC raised its stake in Ocular Therapeutix by 6,760.0% in the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 8,112 shares in the last quarter. 59.21% of the stock is currently owned by institutional investors.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.